The currently available CF drugs, called CFTR modulators, are designed to bind to and correct aberrant CFTR protein, said Jennifer Taylor-Cousar, who treats cystic fibrosis in adults and children at National Jewish Health in Denver, Colorado [and professor of medicine at CU School of Medicine] and co-authored a 2023 review article on modulator therapies.